May 18, 2015
1 min read

FDA grants fast track status to luspatercept for beta-thalassemia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA granted fast track status to luspatercept for patients with transfusion- dependent beta-thalassemia and nontransfusion-dependent beta-thalassemia, according to a press release from the drug’s manufacturer.

Luspatercept (Acceleron and Celgene) —  a modified activin receptor type IIB fusion protein —  acts as a ligand trap for members of the Transforming Growth Factor-Beta superfamily involved in the late stages of red blood cell production.

Unlike erythropoietin, which stimulates the proliferation of early-stage erythrocyte precursor cells, luspatercept regulates late-stage red blood cell precursor cell differentiation and maturation, according to the press release.

Luspatercept is currently being evaluated in a phase 2 trial in patients with beta-thalassemia and myelodysplastic syndromes.

“The FDA’s Fast Track designation for the luspatercept development program recognizes the serious unmet medical needs of patients with beta-thalassemia and the potential for luspatercept in this area,” Jacqualyn A. Fouse, PhD, president of hematology/oncology at Celgene, said in a press release. “Celgene and Acceleron are working diligently to initiate a phase 3 clinical program in 2015 to treat patients with beta-thalassemia and we look forward to continuing to work closely with health authorities and other important stakeholders to advance this program.”